Corvus Pharmaceuticals Inc. [NASDAQ: CRVS] traded at a high on 02/22/21, posting a 21.54 gain after which it closed the day’ session at $4.57. The company report on February 18, 2021 that Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced the completion of its previously announced underwritten public offering of 9,783,660 shares of its common stock, which includes 1,212,231 shares of common stock pursuant to the underwriters’ partial exercise of their option to purchase additional shares of common stock, at a price to the public of $3.50 per share. All shares in the offering were sold by Corvus, with gross proceeds to Corvus of $34.2 million and net proceeds of approximately $31.8 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Cantor Fitzgerald & Co. and H.C. Wainwright & Co. are acting as joint book-running managers for the offering.
The results of the trading session contributed to over 6972152 shares changing hands. Over the past one week, the price volatility of Corvus Pharmaceuticals Inc. stands at 8.41% while the volatility over the past one month is 8.44%.
The market cap for CRVS stock reached $166.53 million, with 29.50 million shares outstanding and 17.82 million shares in the current float. Compared to the average trading volume of 535.95K shares, CRVS reached a trading volume of 6972152 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Corvus Pharmaceuticals Inc. [CRVS]?
Mizuho have made an estimate for Corvus Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on February 10, 2021. The new note on the price target was released on September 12, 2019, representing the official price target for Corvus Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $6, while ROTH Capital analysts kept a Buy rating on CRVS stock.
The Average True Range (ATR) for Corvus Pharmaceuticals Inc. is set at 0.36 The Price to Book ratio for the last quarter was 3.17, with the Price to Cash per share for the same quarter was set at 1.41.
How has CRVS stock performed recently?
Corvus Pharmaceuticals Inc. [CRVS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 30.57. With this latest performance, CRVS shares gained by 17.48% in over the last four-week period, additionally plugging by 14.25% over the last 6 months – not to mention a rise of 11.19% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRVS stock in for the last two-week period is set at 61.13, with the RSI for the last a single of trading hit 65.34, and the three-weeks RSI is set at 58.71 for Corvus Pharmaceuticals Inc. [CRVS]. The present Moving Average for the last 50 days of trading for this stock 3.94, while it was recorded at 3.86 for the last single week of trading, and 3.87 for the last 200 days.
Corvus Pharmaceuticals Inc. [CRVS]: Deeper insight into the fundamentals
Return on Total Capital for CRVS is now -52.92, given the latest momentum, and Return on Invested Capital for the company is -50.80. Return on Equity for this stock declined to -51.44, with Return on Assets sitting at -46.24. When it comes to the capital structure of this company, Corvus Pharmaceuticals Inc. [CRVS] has a Total Debt to Total Equity ratio set at 4.48. Additionally, CRVS Total Debt to Total Capital is recorded at 4.29, with Total Debt to Total Assets ending up at 3.81. Long-Term Debt to Equity for the company is recorded at 3.25, with the Long-Term Debt to Total Capital now at 3.11.
Reflecting on the efficiency of the workforce at the company, Corvus Pharmaceuticals Inc. [CRVS] managed to generate an average of -$880,604 per employee.Corvus Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.40 and a Current Ratio set at 4.40.
Earnings analysis for Corvus Pharmaceuticals Inc. [CRVS]
With the latest financial reports released by the company, Corvus Pharmaceuticals Inc. posted -0.38/share EPS, while the average EPS was predicted by analysts to be reported at -0.33/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -15.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CRVS.